

Résumé of Dr. Natalie Krebs

Name: Dr. Natalie Krebs

Date of birth: September 13, 1971

Place of birth: Bern, Switzerland

Place of residence: Schönried, Switzerland

Nationality: Swiss

Professional qualifications

Until 1997 Degree in medicine from the University of Basel

1999 Doctorate in medicine from the University of Basel

Professional experience

1998-2000 The Boston Consulting Group: Strategic consultant with a fo-

cus on the health care, pharmaceutical and medical technol-

ogy industries

2000-2003 Altium Capital AG: Corporate financing and transaction con-

sultant with a focus on the health care, pharmaceutical and

medical technology industries

2003-2011 Bayer (Schweiz) AG and formerly Schering (Schweiz) AG in var-

ious positions: Senior divisional director, business unit man-

ager, head of external affairs

2017-2020 Various positions on supervisory boards (administrative

boards) in Switzerland (Metalor Dental Holding AG, Metanova

AG, Z Systems AG)

2019-Current Chairwoman of the Supervisory Board of aap Implantate AG

(Berlin)

Relevant knowledge, skills and specialist experience

Dr. Krebs has management and consulting experience in the healthcare and medical technology sectors. In addition, Dr. Krebs is familiar with national and international strategy development, execution and restructuring.

Memberships

Dr. Krebs holds the following positions on other statutory supervisory boards as well as on comparable domestic and foreign controlling bodies of commercial enterprises:

Memberships in supervisory boards

2019-Current aap Implantate AG (Berlin), Chairwoman of the Supervisory

Board

Memberships in comparable domestic or foreign controlling bodies

None

Memberships in charitable/non-profit bodies

2022-Current Member of the Board of Trustees of the Fondation Skifuture

Saanenland

In the opinion of the Supervisory Board, Dr. Krebs does not have a personal or business relationship with the Company, the governing bodies of the Company or a significant shareholder in the Company subject to disclosure in accordance with C.13 of the German Corporate Governance Code. Furthermore, in the opinion of the Supervisory Board, she is independent within the meaning of the German Corporate Governance Code.